donwloadimg

Download App

Log in to access Online Inquiry

领航医药生物科技(00399.HK)中期扭亏为盈至1.25亿港元
Pilot Pharmaceutical Biotechnology (00399.HK) turned from a loss to a profit of HK $125 million in the medium term

格隆滙 ·  {{timeTz}}

格隆汇11月29日丨领航医药生物科技(00399.HK)发布公告,截至2021年9月30日止6个月,公司收益为663.2万港元,同比减少7.27%;公司拥有人应占盈利为1.25亿港元,上年同期亏损为9344.9万港元;每股亏损8.54港仙。

On November 29th, 00399.HK announced that for the six months ended September 30, 2021, the company's income was HK $6.632 million, down 7.27% from the same period last year; the profit attributable to the company's owners was HK $125 million, compared with a loss of HK $93.449 million in the same period last year; a loss of HK8.54 cents per share.

公告称,转亏为盈乃主要由于可换股债券三完成第二次修订而产生的非现金项目所致。可换股债券三已重列至可换股债券三于完成日负债部分的公平值(比其账面值低)。负债部分账面值与公平值之间的差异约为2.51亿港元,已计入本财政期间的收益表内。

The announcement said that the turn from loss to profit was mainly due to the non-cash items resulting from the completion of the second revision of the convertible bonds. Convertible Bond III has been reclassified to the fair value of the liability portion of Convertible Bond III at the completion date (lower than its carrying amount). The difference between the carrying amount and fair value of the liability portion is approximately HK $251 million and has been included in the income statement for the current financial period.

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal.


Moomoo is a financial information and trading app offered by Moomoo Techonologies Inc.


In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).


In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. ("Moomoo Financial SG") regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial SG is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.


In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.